Ixiaro is indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV) and is approved for use in individuals 2 months of age and older.
Ixiaro was approved in the US on March 30, 2009, which is also its international birthdate.
Currently, Ixiaro is licensed in Australia, New Zealand, Europe, Canada, Switzerland, Hong Kong, Singapore, and Israel.
Japanese encephalitis (JE) virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific.
For most travelers to Asia, the risk for JE is very low but varies based on the destination, length of travel, season, and activities.